Kevin Zorn, MD, on preserving ejaculation with BPH therapies

Preservation of ejaculatory function is a top priority among men undergoing treatment for benign prostatic hyperplasia (BPH), according to Kevin C. Zorn, MD, FRCSC, FACS.

Zorn recently delivered a talk titled, “State-of-the-Art Lecture: Preservation of Ejaculatory Function with BPH Treatments,” at the 2025 American Urological Association (AUA) Annual Meeting in Las Vegas, Nevada. In an interview with Urology Times®, Zorn recapped key takeaways from this session.

“More than ever, I think one of the key issues is that the standard of care interview during a BPH consultation needs to address, needs to bring up, needs to counsel men in the various type of therapies that exist from resective, like TURP or open prostatectomy, HoLEP, to now, the MISTs, and to understand that the techniques we have with MISTs can address LUTS, the urinary symptoms, and preserve ejaculation. Because once it's lost, it's lost. I don't think it will be coming back,” he explained.

Zorn is the founder/director of BPH Canada in Montreal.

Zorn then touched on historical context of BPH surgeries, noting the evolution from concerns about mortality to concerns about bleeding and sexual function, with Aquablation offering real-time visualization and preservation of the ejaculatory duct. Future advancements, he noted, may also include stents and vaccines to prevent BPH.

Overall, Zorn concluded, “Will we see a day where 100% of men can preserve their ejaculation? I think it's possible. We just have to see it, we can treat it, we can protect it. And finally, the idea of where we're going to go with all these new technologies and stents is to be seen, and then the durability of all these new technologies.”